President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Mexico and China — as he has increasingly spoken of the U.S. taking Greenland off Denmark’s hands. Danish multinational pharmaceutical giant Novo Nordisk is the sole owner of semaglutide ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

For Novo Nordisk, a company still rooted in principles ... This is particularly the case in developing nations, from Mexico to the Gulf States, China and India, where healthcare systems are ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Simply sign up to the European companies myFT Digest -- delivered directly to your inbox. Luxury goods maker LVMH regained its crown as the largest company in Europe on Friday, after shares in ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...